Translational and Regulatory Sciences
Online ISSN : 2434-4974
TS
Drug reprofiling and repurposing: a state-of-the-art public-private collaboration model
Hiroshi NAGABUKURONaoto UEMURA
Author information
JOURNALS OPEN ACCESS FULL-TEXT HTML

2020 Volume 2 Issue 2 Pages 47-50

Details
Abstract

Drug repurposing is being actively pursued as a cost- and time-efficient drug discovery and development strategy. We proposed a new public-private partnership model for drug repurposing that involves academic institutions, government, investors, pharmaceutical and biotech companies. The model initially identifies promising hypothesis based on information of pharma assets on shelves, and proves the hypothesis in early clinical settings through academic and industry collaborations. We are currently developing multiple clinical assets including ART-001, a novel PI3Kα inhibitor for complex vascular malformations, based on this strategy to prove the model as a highly productive drug discovery and drug development framework.

Information related to the author
© 2020 Catalyst Unit

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Previous article Next article
feedback
Top